ライフサイエンスコーパス: pancreaticoduodenectomy

1 resection (EA or SA) and en bloc resection (pancreaticoduodenectomy).

2 had N1 disease; 138 patients (78%) underwent pancreaticoduodenectomy.

3 everal reports of collected experiences with pancreaticoduodenectomy.

4 ome increased morbidity compared to standard pancreaticoduodenectomy.

5 neal lymphadenectomy to a pylorus-preserving pancreaticoduodenectomy.

6 cations and death associated with subsequent pancreaticoduodenectomy.

7 rioperative morbidity and mortality rates of pancreaticoduodenectomy.

8 isk for postoperative wound infections after pancreaticoduodenectomy.

9 reas not associated with an IPMN resected by pancreaticoduodenectomy.

10 ed in 300 consecutive patients who underwent pancreaticoduodenectomy.

11 for surgical-site infection (SSI) after open pancreaticoduodenectomy.

12 creatic fistula or total complications after pancreaticoduodenectomy.

13 e-institution experience assessing QOL after pancreaticoduodenectomy.

14 a few small studies have evaluated QOL after pancreaticoduodenectomy.

15 y and mortality rates in patients undergoing pancreaticoduodenectomy.

16 nd poorly known long-term complication after pancreaticoduodenectomy.

17 ard pancreaticoduodenectomy and 58 a radical pancreaticoduodenectomy.

18 inage on morbidity and mortality rates after pancreaticoduodenectomy.

19 management may improve patient outcome after pancreaticoduodenectomy.

20 similar morbidity and mortality to standard pancreaticoduodenectomy.

21 e been observed at high-volume centers after pancreaticoduodenectomy.

22 chemoradiation given either before or after pancreaticoduodenectomy.

23 oradiation because of delayed recovery after pancreaticoduodenectomy.

24 and after open transhiatal esophagectomy or pancreaticoduodenectomy.

25 r to complete tumor resection at the time of pancreaticoduodenectomy.

26 uperiority in the operative time compared to pancreaticoduodenectomy.

27 duction in tumor size and underwent standard pancreaticoduodenectomy.

28 mptive completion pancreatectomy through the pancreaticoduodenectomy.

29 isional SSI as well as organ/space SSI after pancreaticoduodenectomy.

30 factor of gastric stump carcinoma following pancreaticoduodenectomy.

31 preoperative multidetector CT and subsequent pancreaticoduodenectomy.

32 short-term outcomes to those following open pancreaticoduodenectomy.

33 for pancreatic cancer patients who underwent pancreaticoduodenectomy.

34 ally lethal postoperative complication after pancreaticoduodenectomy.

35 total hip replacement (THR), colectomy, and pancreaticoduodenectomy.

36 nign or malignant disease requiring elective pancreaticoduodenectomy.

37 ilar results were obtained for colectomy and pancreaticoduodenectomy.

38 ated with a high risk of complications after pancreaticoduodenectomy.

39 eatic adenocarcinoma, 202 patients underwent pancreaticoduodenectomy.

40 pularized by Whipple in 1935, who reported 3 pancreaticoduodenectomies.

41 ee options for postoperative treatment after pancreaticoduodenectomy: 1) standard therapy: external b

42 consistent among 220 patients who underwent pancreaticoduodenectomy (10% vs. 21%; relative risk, 0.4

43 Procedures included 9 pancreaticoduodenectomies, 10 distal pancreatectomies, a

44 Five patients required pancreaticoduodenectomy, 11 patients underwent non-Whipp

45 as 56.6%, 19.9%, and 23.3%, respectively.For pancreaticoduodenectomies (12,670 patients; mortality 9.

46 robotic pancreatic resections were analyzed; pancreaticoduodenectomy (132), distal pancreatectomy (83

47 eventy-two percent of the patients underwent pancreaticoduodenectomies, 15% underwent total pancreate

48 pancreatectomy (40%), enucleation (34%), and pancreaticoduodenectomy (16%) were the most common proce

49 There were 118 consecutive resections (51 pancreaticoduodenectomies, 18 total pancreatectomies, an

50 re was required in 16 patients (6%) (11 with pancreaticoduodenectomy, 2 with distal pancreatectomy, 2

51 olved the gland, with 70% being resected via pancreaticoduodenectomy, 22% via total pancreatectomy, a

52 Fifty-nine patients underwent pancreaticoduodenectomy, 36 without venous resection and

53 11 (63%) colectomy/proctectomy, 38,167 (14%) pancreaticoduodenectomy, 40,328 (14%) lung resection, 16

54 g colonic surgery and 10 patients undergoing pancreaticoduodenectomy, 6 cm colon or jejunum was isola

55 28% underwent pancreaticoduodenectomy, 61% PSD, and 11% segmental duod

56 oportion of total pancreatectomy (74.7%) and pancreaticoduodenectomy (78.3%) patients had N1 disease

57 d with higher 30-day mortality compared with pancreaticoduodenectomy (8.0% vs. 1.5%, respectively; P

58 A total of 7061 patients underwent pancreaticoduodenectomy: 983 had MIPD and 6078 had open

59 re were no differences between MIPD and open pancreaticoduodenectomy after multivariable adjustment i

60 ancreatectomy, 4 total pancreatectomy, and 4 pancreaticoduodenectomy); all had dysplastic intraductal

61 n 16 patients (8 men and 8 women) undergoing pancreaticoduodenectomy, an isolated part of jejunum was

62 Thirty-eight pancreaticoduodenectomies and 23 duodenum-preserving pan

63 ommon procedures was 529 +/- 103 minutes for pancreaticoduodenectomy and 257 +/- 93 minutes for dista

64 patients randomized, 56 underwent a standard pancreaticoduodenectomy and 58 a radical pancreaticoduod

65 Pancreaticoduodenectomy and distal pancreatectomy are as

66 ophylactic octreotide in patients undergoing pancreaticoduodenectomy and found no benefit to the use

67 nce occurred in 21% of patients who received pancreaticoduodenectomy and postoperative chemoradiation

68 ory surgery with the purpose of performing a pancreaticoduodenectomy and were found to have unresecta

69 m volume threshold for hospitals to perform (pancreaticoduodenectomy) and the high-volume center.

70 ocedure, 2 patients had a pylorus-preserving pancreaticoduodenectomy, and 1 patient had a distal panc

71 (>/=65 years of age) undergoing gastrectomy, pancreaticoduodenectomy, and colectomy at a 2000-bed urb

72 perative rapid-fractionation chemoradiation, pancreaticoduodenectomy, and EB-IORT is associated with

73 alternative to high-risk anastomosis during pancreaticoduodenectomy; and distal pancreatectomy for b

74 The forbidding mortality of pancreaticoduodenectomy, approximately 20% just a genera

75 exploratory surgery with intent to perform a pancreaticoduodenectomy are found to have unresectable d

76 tage disease; rates of 5-year survival after pancreaticoduodenectomy are low.

77 Operative mortality rates for pancreaticoduodenectomy are now <5% at major centers, an

78 tinue to accumulate about pylorus preserving pancreaticoduodenectomy as an alternative to the standar

79 database of patients who underwent elective pancreaticoduodenectomy at an academic tertiary care cen

80 I-III) between 2004 to 2016 who underwent a pancreaticoduodenectomy at hospitals across the US repor

81 ection specimens from patients who underwent pancreaticoduodenectomy at Johns Hopkins Hospital (Balti

82 Among 1,648 patients undergoing pancreaticoduodenectomy at the authors' institution from

83 Of 5025 patients who underwent pancreaticoduodenectomy at the Johns Hopkins Hospital an

84 d to select records of patients undergoing a pancreaticoduodenectomy between 1984 and 1995.

85 ution, high-volume experience indicates that pancreaticoduodenectomy can be performed safely for a va

86 Pancreaticoduodenectomy can be performed with a similar

87 Radical (extended) pancreaticoduodenectomy can be performed with similar mo

88 There is a general impression that pancreaticoduodenectomy can severely impair QOL and alte

89 etroperitoneal lymphadenectomy to a standard pancreaticoduodenectomy) can be performed with similar m

90 use of AC among older adults who underwent a pancreaticoduodenectomy comparing rates in 2004 vs 2016.

91 aim of this study was to study whether post-pancreaticoduodenectomy complications (PPDC) in high-ris

92 These results demonstrate that, as with pancreaticoduodenectomy, distal pancreatectomy can be pe

93 Pancreatic resections, including pancreaticoduodenectomy, distal pancreatectomy, and tota

94 who received preoperative chemoradiation and pancreaticoduodenectomy experienced a local recurrence;

95 s is increased in patients undergoing staged pancreaticoduodenectomy followed by liver-directed thera

96 A total of 405 patients underwent pancreaticoduodenectomy for adenocarcinoma of the head o

97 herapy significantly improves survival after pancreaticoduodenectomy for adenocarcinoma of the head,

98 ears to be indicated for patients treated by pancreaticoduodenectomy for adenocarcinoma of the head,

99 radiation therapy has been recommended after pancreaticoduodenectomy for adenocarcinoma of the head,

100 patients who underwent potentially curative pancreaticoduodenectomy for adenocarcinoma of the pancre

101 Data on all patients undergoing pancreaticoduodenectomy for adenocarcinoma of the pancre

102 ure due to prolonged survival observed after pancreaticoduodenectomy for benign and premalignant lesi

103 formed of 72 consecutive patients undergoing pancreaticoduodenectomy for chronic pancreatitis between

104 ter study of preoperative chemoradiation and pancreaticoduodenectomy for localized pancreatic adenoca

105 Patients undergoing pancreaticoduodenectomy for LPSP have durable relief of

106 The routine use of octreotide after pancreaticoduodenectomy for malignancy cannot be recomme

107 ver, in the subset of patients who underwent pancreaticoduodenectomy for malignancy, either no analys

108 cidence of pancreatic anastomotic leak after pancreaticoduodenectomy for malignancy.

109 erative day 5) or no further treatment after pancreaticoduodenectomy for malignancy.

110 astric stump carcinoma 19 and 10 years after pancreaticoduodenectomy for malignant ampulloma and tota

111 nsecutive group of 45 patients who underwent pancreaticoduodenectomy for PA from July 2001 to Decembe

112 Since 1995, patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma ha

113 ned to evaluate prospectively survival after pancreaticoduodenectomy for pancreatic adenocarcinoma, c

114 odenectomy for malignant ampulloma and total pancreaticoduodenectomy for pancreatic adenocarcinoma, r

115 utcome of 64 consecutive patients undergoing pancreaticoduodenectomy for pancreatic carcinoma with gr

116 T) have reduced postoperative survival after pancreaticoduodenectomy for pancreatic ductal adenocarci

117 For patients who undergo pancreaticoduodenectomy for pancreatic ductal adenocarci

118 o guide surgical management in IONM-positive pancreaticoduodenectomy for patients receiving neoadjuva

119 ce is often considered a contraindication to pancreaticoduodenectomy for patients with malignant tumo

120 improved long-term survival associated with pancreaticoduodenectomy for patients with pancreatic car

121 gin following initial IONM positivity during pancreaticoduodenectomy for PDAC are conflicting, they s

122 tility of re-resecting positive IONMs during pancreaticoduodenectomy for PDAC.

123 es have significantly reduced survival after pancreaticoduodenectomy for PDAC.

124 p of patients treated 5 or more years ago by pancreaticoduodenectomy for periampullary adenocarcinoma

125 PV confluence may be performed safely during pancreaticoduodenectomy for periampullary malignant tumo

126 nastomoses is a major late complication of a pancreaticoduodenectomy for the treatment of a periampul

127 s of retroperitoneal margin positivity after pancreaticoduodenectomy for tumors of the pancreatic hea

128 ne institution increased its yearly share of pancreaticoduodenectomies from 20.7% to 58.5%, and the s

129 Patients who underwent reoperative pancreaticoduodenectomy had an increased incidence of pa

130 Fifty-eight percent of patients undergoing pancreaticoduodenectomy had an uncomplicated postoperati

131 Hospitals with more years of experience with pancreaticoduodenectomy had lower rates of inpatient mor

132 Pancreaticoduodenectomy has become a commonly performed

133 Pancreaticoduodenectomy has been used increasingly in re

134 The drive to reduce LOS after pancreaticoduodenectomy has minimal effect on overall ch

135 strate that as a group, patients who survive pancreaticoduodenectomy have near-normal QOL scores.

136 al Quality Improvement Program who underwent pancreaticoduodenectomy, hepatectomy, and colectomy at a

137 he volume and type of fluid administered for pancreaticoduodenectomy impacts postoperative outcomes.

138 modality therapy and avoids the toxicity of pancreaticoduodenectomy in patients found to have metast

139 The authors define the role of palliative pancreaticoduodenectomy in patients with pancreatic carc

140 These data support the role of palliative pancreaticoduodenectomy in patients with pancreatic carc

141 consecutive group of 650 patients undergoing pancreaticoduodenectomy in the 1990s.

142 he reported advantages of minimally invasive pancreaticoduodenectomy include better visualization, fa

143 ndergoing standard versus radical (extended) pancreaticoduodenectomy (including distal gastrectomy an

144 e technical challenges of minimally invasive pancreaticoduodenectomy, including robotic techniques.

145 Pancreaticoduodenectomy is accompanied by a considerable

146 impact of residual microscopic disease after pancreaticoduodenectomy is currently a point of controve

147 Pancreaticoduodenectomy is gaining acceptance and is bei

148 Survival after pancreaticoduodenectomy is not improved by extending pan

149 tive trial of regional pancreatectomy versus pancreaticoduodenectomy is warranted in previously untre

150 ectomy, coronary artery bypass graft (CABG), pancreaticoduodenectomy, lung resection, or esophagectom

151 erest in expanding use of minimally invasive pancreaticoduodenectomy (MIPD).

152 ctomy (n = 8), hepatic resection (n = 4), or pancreaticoduodenectomy (n = 1) underwent MR cholangiogr

153 underwent total pancreatectomy (n = 100) or pancreaticoduodenectomy (n = 1286) for adenocarcinoma we

154 by site in the reoperative group undergoing pancreaticoduodenectomy (n = 52) was 60%, 19%, 15%, and

155 ive drainage still has a role during Whipple pancreaticoduodenectomy on the basis of the results of a

156 patients is free of disease 16 months after pancreaticoduodenectomy, one is alive and free of tumor

157 have several potential advantages over open pancreaticoduodenectomy (OPD), including lower blood los

158 All patients who underwent a pancreaticoduodenectomy or a duodenum-preserving pancrea

159 operative pasireotide in patients undergoing pancreaticoduodenectomy or distal pancreatectomy [POPF:

160 hrough a formal pancreatic resection such as pancreaticoduodenectomy or distal pancreatectomy.

161 us pasireotide in patients undergoing either pancreaticoduodenectomy or distal pancreatectomy.

162 trend in Maryland toward regionalization of pancreaticoduodenectomy over a 12-year period and its ef

163 A trend toward regionalization of pancreaticoduodenectomy over a 12-year period in Marylan

164 mproved significantly in patients undergoing pancreaticoduodenectomy (p < 0.02).

165 ng total pancreatectomy (69.0% vs. 38.6% for pancreaticoduodenectomy; P < 0.0001), most complications

166 ycerol were analysed from small intestine of pancreaticoduodenectomy patients before and after occlud

167 Total pancreatectomy and pancreaticoduodenectomy patients had comparable 5-year s

168 Overall QOL scores for the 192 responding pancreaticoduodenectomy patients in the three domains (p

169 The pancreaticoduodenectomy patients were subgrouped into ch

170 We reviewed 1944 consecutive pancreaticoduodenectomies (PD) over an 8-year period (Ap

171 different surgical techniques, standard (ST) pancreaticoduodenectomy (PD) and no-touch isolation (NT)

172 in the cohort 451 patients (83%) underwent a pancreaticoduodenectomy (PD) and the most common indicat

173 Wound infections after pancreaticoduodenectomy (PD) are common.

174 Pancreaticoduodenectomy (PD) can be associated with sign

175 cidence of biliary stricture formation after pancreaticoduodenectomy (PD) for benign and malignant pe

176 During pancreaticoduodenectomy (PD) for ductal adenocarcinoma,

177 ociated with OS among patients who underwent pancreaticoduodenectomy (PD) for pancreatic cancer.

178 This study compares outcomes following pancreaticoduodenectomy (PD) for patients treated at loc

179 addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/I

180 erative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic a

181 mortality, and length of hospital stay after pancreaticoduodenectomy (PD) have significantly decrease

182 heme in a large cohort of patients following pancreaticoduodenectomy (PD) in a pancreaticobiliary sur

183 The pancreaticoduodenectomy (PD) is a resource-intensive pro

184 eta-analysis was to evaluate whether robotic pancreaticoduodenectomy (PD) may provide better clinical

185 in jaundiced patients who are candidates for pancreaticoduodenectomy (PD) or major hepatectomy due to

186 Patients eligible for pancreaticoduodenectomy (PD) or pylorus-preserving PD (P

187 portal vein thrombosis (PVT) risk following pancreaticoduodenectomy (PD) or total pancreatectomy (TP

188 use of preoperative biliary drainage before pancreaticoduodenectomy (PD) remains controversial.

189 ting, and Participants: Hospitals performing pancreaticoduodenectomy (PD) were queried from the Unive

190 Although pancreaticoduodenectomy (PD) with en-bloc portal vein/su

191 D-IPMN, including the following: (1) initial pancreaticoduodenectomy (PD), (2) yearly noninvasive rad

192 PF is a major complication following pancreaticoduodenectomy (PD), associated with significan

193 with total parenteral nutrition (TPN), after pancreaticoduodenectomy (PD), in terms of postoperative

194 ent operations (PAO) impacts the outcomes of pancreaticoduodenectomy (PD).

195 dds ratio = 0.73-0.77, P < 0.001) after open pancreaticoduodenectomy (PD).

196 a large cohort of patients >/=5-years after pancreaticoduodenectomy (PD).

197 ist comparing robotic and open approaches to pancreaticoduodenectomy (PD).

198 is the major contributor to morbidity after pancreaticoduodenectomy (PD).

199 s one of the most common complications after pancreaticoduodenectomy (PD).

200 2015, we randomized 330 patients undergoing pancreaticoduodenectomy (PD, n = 218), central (n = 16),

201 lity 9.2%), there were 2 cut-offs (16 and 40 pancreaticoduodenectomies per year), and both were indep

202 lesions were identified in pancreata from 33 pancreaticoduodenectomies performed for infiltrating ade

203 rate lower morbidity and mortality rates for pancreaticoduodenectomy performed at high-volume centers

204 Two hundred forty consecutive cases of pancreaticoduodenectomy performed between January 1994 a

205 directed therapy (14.5%) versus simultaneous pancreaticoduodenectomy plus liver-directed therapy (7.0

206 Pancreaticoduodenectomy plus liver-directed therapy is a

207 Prolonged recovery after pancreaticoduodenectomy prevents the delivery of postope

208 patients After duodenal resection, including pancreaticoduodenectomy, PSD, or segmental duodenectomy,

209 = .049) were predictive of relapse, whereas pancreaticoduodenectomy reduced the relapse rate (vs the

210 had lower rates of inpatient mortality after pancreaticoduodenectomy relative to very-low-volume faci

211 ive intraoperative neck margin (IONM) during pancreaticoduodenectomy remains controversial.

212 atients were randomized to either a standard pancreaticoduodenectomy (removing only the peripancreati

213 were randomized to receive either a standard pancreaticoduodenectomy (removing only the peripancreati

214 r complex pancreatic resections, such as the pancreaticoduodenectomy, requires close monitoring of ou

215 (90.7% vs. 91.8%) (total pancreatectomy vs. pancreaticoduodenectomy, respectively, both P > 0.05).

216 (22.2% vs. 43.7%) (total pancreatectomy vs. pancreaticoduodenectomy, respectively, both P < 0.0001).

217 evious history of diabetes but scheduled for pancreaticoduodenectomy resulting in the acute reduction

218 e patient in the radical group with negative pancreaticoduodenectomy specimen lymph nodes had a micro

219 feasibility of performing spleen-preserving pancreaticoduodenectomy (SPPD).

220 c with the specimen) or a radical (extended) pancreaticoduodenectomy (standard resection plus distal

221 odes en bloc with the specimen) or a radical pancreaticoduodenectomy (standard resection plus distal

222 cal resection procedures such as the radical pancreaticoduodenectomy, subtotal and partial hepatectom

223 ondiabetic patients, scheduled for identical pancreaticoduodenectomy surgery, underwent oral glucose

224 Pancreaticoduodenectomy (the Whipple procedure) is the o

225 me-outcome relation for hospitals performing pancreaticoduodenectomy (the Whipple procedure).

226 xploration underwent successful resection by pancreaticoduodenectomy; the remaining 26 patients (34%)

227 with periampullary adenocarcinoma treated by pancreaticoduodenectomy, those with duodenal adenocarcin

228 Eight weeks after pancreaticoduodenectomy, three patients received 1 x 10(

229 Total laparoscopic pancreaticoduodenectomy (TLPD) has been demonstrated to

230 er, most surgeons remain hesitant to perform pancreaticoduodenectomy unless surgical margins are wide

231 evaluating surgical incision closure during pancreaticoduodenectomy using negative pressure wound th

232 re used to examine whether hospital share of pancreaticoduodenectomies was a significant predictor of

233 length of postoperative hospital stay after pancreaticoduodenectomy was 18.4 days, which was signifi

234 e overall postoperative morbidity rate after pancreaticoduodenectomy was 48% (114/240).

235 3%, whereas the in-hospital mortality after pancreaticoduodenectomy was 5%.

236 First, pancreaticoduodenectomy was challenging in the infant do

237 rvival following total pancreatectomy versus pancreaticoduodenectomy was equivalent.

238 A pancreaticoduodenectomy was performed in 139 patients an

239 Pancreaticoduodenectomy was performed in 174 patients, w

240 Pancreaticoduodenectomy was performed in 71% of patients

241 ish literature in which a minimally invasive pancreaticoduodenectomy was performed.

242 en March 1969 and May 2003, 1000 consecutive pancreaticoduodenectomies were performed by a single sur

243 A total of 795 pancreaticoduodenectomies were performed in Maryland at

244 During this period, 190 consecutive pancreaticoduodenectomies were performed without a morta

245 2011 and November 2013, patients undergoing pancreaticoduodenectomy were enrolled in an institutiona

246 Adult patients undergoing pancreaticoduodenectomy were identified from the Nationa

247 Common problems after pancreaticoduodenectomy were weight loss, abdominal pain

248 some procedures (eg, open colectomy and open pancreaticoduodenectomy), whereas the opposite is true i

249 ieved in centers performing large numbers of pancreaticoduodenectomies, which suggests that regionali

250 titutional study of 1399 patients undergoing pancreaticoduodenectomy, which demonstrated that in comp

251 nd (EUS), surgery in ZES patients with MEN1, pancreaticoduodenectomy (Whipple procedure), lymph node

252 distal pancreatectomy, and the remaining had pancreaticoduodenectomy (Whipple resection).

253 tionnaire was sent to 323 patients surviving pancreaticoduodenectomy who had undergone surgery at The

254 as determined in 15 patients who underwent a pancreaticoduodenectomy with a combination of laser Dopp

255 erence, the high risk of complications after pancreaticoduodenectomy with a mortality of 5%; maintena

256 rily require immediate laparotomy to undergo pancreaticoduodenectomy with acceptable morbidity and mo

257 nd patients with localized disease underwent pancreaticoduodenectomy with EB-IORT 10 to 15 Gy.

258 aken to surgery, 20 patients (74%) underwent pancreaticoduodenectomy with EB-IORT.

259 The authors sought to determine whether pancreaticoduodenectomy with en bloc resection of the SM

260 Two hundred eleven patients underwent pancreaticoduodenectomy with pancreatic-enteric anastomo

261 e preoperative biopsy was negative underwent pancreaticoduodenectomy with planned postoperative chemo

262 Pancreaticoduodenectomy with postoperative chemotherapy

263 These data demonstrate that radical pancreaticoduodenectomy (with the addition of a distal g

264 ead resection offer outcomes as effective as pancreaticoduodenectomy, with lowered morbidity and mort

265 Four patients have undergone pancreaticoduodenectomy without perioperative complicati